Francisco D. Salva
Known title: President and CEOCIK: 0001834051
Francisco D. Salva's purchase track record
Francisco D. Salva has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/13/2024 | AZTR | $100K | -79.8% | -97.3% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AZTR | ▼ Sell | Other | 4,064,050 | — | 6/16/2026 | View on chart |
| AZTR | ▲ Buy | Open Market | 333,300 | $100K | 2/13/2024 | View on chart |
| AZTR | ▲ Buy | Grant | 5,000 | $25K | 6/21/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
Azitra Announces $3.5M Common Stock Sale Agreement and Updated Valuation
Azitra Inc. entered a sales agreement with A.G.P. to offer up to $3.5 million of common stock. The company also updated its valuation to reflect progress in its cosmetic and EGFRi rash programs. These developments were noted in a Benzinga report that listed Azitra among 12 healthcare stocks moving in Thursday’s after‑market session.
Azitra Announces $3.5M Common Stock Sale Agreement and Updated Valuation. Azitra Inc. entered a sales agreement with A.G.P. to offer up to $3.5 million of common stock. The company also updated its valuation to reflect progress in its cosmetic and EGFRi rash programs. These developments were noted in a Benzinga report that listed Azitra among 12 healthcare stocks moving in Thursday’s after‑market session.